ispronicline ispronicline ispronicline (tc-1734, azd-3480) is an experimental drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. it progressed to phase ii clinical trials for the treatment of dementia and alzheimer's disease, but is no longer under development. isproniclineclinical dataatc codenoneidentifiers iupac name (2s,4e)-5-(5-isopropoxypyridin-3-yl)-n-methylpent-4-en-2-amine cas number252870-53-4 ypubchem cid9824145chemspider7999892 nunii3e05nbh9v5keggd08935 ychemical and physical dataformulac14h22n2omolar mass234.336 g·mol−13d model (jsmol)interactive image smiles c(c/c=c/c1=cc(=cn=c1)oc(c)c)nc inchi inchi=1s/c14h22n2o/c1-11(2)17-14-8-13(9-16-10-14)7-5-6-12(3)15-4/h5,7-12,15h,6h2,1-4h3/b7-5+/t12-/m0/s1 nkey:rpcviaxdaumjjp-pzbablghsa-n n ny (what is this?) (verify) it has also progressed to phase ii as a potential treatment for adhd. with dosages of 50mg day showing a significant improvement in adhd symptoms ispronicline is subtype-selective, binding primarily to the α4β2 subtype. it has antidepressant, nootropic and neuroprotective effects. early stage clinical trials showed that ispronicline was well tolerated, with the main side effects being dizziness and headache. however, mid stage clinical trials failed to show sufficient efficacy to continue development as a pharmaceutical drug.